AstraZeneca PLC (LSE:LON:AZN) announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized the potential of its drug Imfinzi (durvalumab) for treating resectable non-small cell lung cancer (NSCLC). The acknowledgment is based on the positive results of the AEGEAN Phase III trial, which demonstrated that Imfinzi met the primary endpoint of event-free survival (EFS) with a tolerable safety profile.
The ODAC, providing expert advice to the FDA, noted that although the specific contributions of the neoadjuvant and adjuvant phases could not be distinctly determined due to the trial's design, the Imfinzi regimen before and after surgery could be significant for patient care. Imfinzi, in combination with neoadjuvant chemotherapy, has shown a 32% reduction in the risk of disease recurrence or death compared to chemotherapy alone, at a data maturity of 32%.
John V. Heymach, MD, PhD, highlighted the pressing need for new treatments, pointing out that many patients with resectable lung cancer experience disease recurrence after surgery and chemotherapy. Imfinzi's use before and after surgery could substantially increase the time patients live without disease progression or recurrence.
Susan Galbraith, Executive Vice President of AstraZeneca (NASDAQ:AZN), expressed the company's commitment to working with the FDA to provide this new immunotherapy option to patients. The regimen's flexibility with different chemotherapy backbones could be beneficial for those with resectable lung cancer.
The AEGEAN trial's interim analysis showed a pathologic complete response (pCR) rate of 17.2% with Imfinzi plus chemotherapy before surgery, compared to 4.3% with chemotherapy alone. Imfinzi was well tolerated, with no new safety concerns identified in both the neoadjuvant and adjuvant settings.
The FDA, while not obligated to follow the ODAC's recommendations, will take them into account during its review process. Imfinzi has already been approved in Switzerland and the UK for resectable NSCLC based on the AEGEAN trial results, with ongoing reviews in the EU, China, and other countries.
Imfinzi is currently the only approved immunotherapy for unresectable, Stage III NSCLC patients who have not progressed following chemoradiotherapy, as per the PACIFIC Phase III trial. AstraZeneca's commitment to advancing lung cancer treatment is evident in its broad portfolio and numerous ongoing trials for various cancer types. This information is based on a press release statement.
In other recent news, AstraZeneca reported a significant increase in its revenue for the first half of 2024, reaching almost $13 billion in the second quarter, marking an 18% increase. The company also saw its core operating profit rise to $8.4 billion. AstraZeneca's upgraded full-year guidance now anticipates mid-teens percentage increases in both total revenue and core EPS.
The company attributed this growth to positive phase 3 trial results, new drug approvals, and strong performance in major markets such as the U.S., Europe, and China. The company's CEO expressed confidence in meeting their 2030 goals, which include achieving $80 billion in total revenue and launching at least 20 new medicines.
AstraZeneca is also on track to meet its strategic goals, including a rich pipeline with over 40 phase 3 trials expected to report before the end of 2025. The company is focusing on biospecifics, cell therapy, ADCs, and radioconjugates while maintaining investment in small molecules for smaller indications.
InvestingPro Insights
As AstraZeneca PLC (LSE:AZN) continues to make strides in the oncology field, investors might be intrigued by the company's financial health and market position. According to InvestingPro data, AstraZeneca boasts a substantial market capitalization of 242.86 billion USD, reflecting its significant presence in the pharmaceutical industry. With a Price/Earnings (P/E) ratio of 37.52, the company trades at a higher earnings multiple, which may suggest market optimism about its growth prospects, particularly in light of the recent developments with Imfinzi.
InvestingPro Tips indicate that while AstraZeneca is expected to see net income growth this year, analysts have revised their earnings downwards for the upcoming period, which could be a point of consideration for investors. Additionally, the company has been a consistent dividend payer, maintaining payments for 32 consecutive years, which could appeal to income-focused investors. It's worth noting that AstraZeneca operates with a moderate level of debt and its cash flows can sufficiently cover interest payments, providing a degree of financial stability.
For readers interested in a deeper dive into AstraZenica's financial metrics and additional insights, InvestingPro offers more tips on the company's performance and outlook. Use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking access to a total of 15 additional InvestingPro Tips that can guide investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.